B+
Bull case
25%
Probability
Target price
$58.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
ELVN
Enliven TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Primary-source guidance still supports a live de-risking path in 2026: additional ENABLE data, FDA alignment, and planned ENABLE-2 initiation, while cash of about $462.6 million was said to fund operations into 1H29 [#PR-2026-03-03] [#10-K-2026-03-03].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -10.2.
What can break
Despite runway into 1H29, the company remains pre-revenue and long-term value still depends on future clinical success and capital access.
Momentum
17
Value
41
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $58.00 · Bear $24.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $73.92
Why
Momentum17 · Δ7d +9.7
Value41 · Δ7d -0.1
Sentiment48 · Δ7d -10.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -10.2.
Contradictions & invalidation
- • Despite runway into 1H29, the company remains pre-revenue and long-term value still depends on future clinical success and capital access.
- • ELVN-001 is the core value driver, so any weaker-than-expected ENABLE updates would have outsized impact.
- • The thesis remains heavily dependent on one lead asset and on translating encouraging early data into a registrational program; FDA design feedback, data durability, or Phase 3 timing slippage would likely hit the stock disproportionately [#PR-2026-03-03] [#10-K-2026-03-03].
Catalyst clock
2026-06-30
Additional Phase 1 ENABLE data mid-2026
Lead driver: Sentiment · See AI snapshot
Momentum
17
8% active weight
Current posture
7d trendImproving
Δ7d
+9.7
Δ21d
-10.4
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
48
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.2
Δ21d
+5.4
Why this grade
Composite grade D. Momentum 17.4 / Value 40.6 / Sentiment 48.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$3.04B
Beta
0.33
Shares Out
73.27M
P/E (TTM) · Derived
-22.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-39.28
Rev YoY
-
EPS YoY
+1.0%
Gross Margin
-
Op Margin
-
Net Debt
-$462.22M
Current Ratio
64.07
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data